Saturday, May 31, 2025
23 C
Bengaluru

An Infectious Disease Specialist Speaks to Pharma on How it Needs to Change its Approach

linkedin.com/in/dr-mandar-kubal-3721352

Key Point from the Q &A with Dr. Mandar Kubal, Mumbai

Telemedicine has become a very useful tool for clinicians to manage their patients.

Given the ever changing contours of Covid19 treatment, doctors have to check daily for online resources.

It would be wonderful if pharma can provide every specialty the latest developments in treating Covid19 with pre existing conditions instead of sending their unvaccinated field force to give brand reminders.

Pharma should seek frontline worker status for Medical Reps and Field Managers as they are critical to maintain the drug supply chain.

Treat the Field Force as an asset and protect them, instead of pushing them onto the field without vaccination.

And many more insights from a clinician at the frontlines of treating Covid19 patients.

An Infectious Disease Specialist Speaks to Pharma on How it Needs to Change its Approach @YouTube

………………………………………………………………………………………………………………………….

Digital Excellence Pharma Academy (DEPA) begins a new series of conversations with doctors to Indian Pharma and insight into their challenges and how pharma needs to change its current approach to interactions with doctors

Great Opportunity for Pharma People to Listen to What Doctors have to Say https://youtu.be/wqCK574qb-g
Conversation with Dr. Deepak Krishnamurthy on Expectations of Doctors from Pharma https://youtu.be/7VVzhMlY2Uw

You can also listen to what pharma leaders from across the globe have to say about various aspects of pharma’s challenges and solutions on MedicinMan YouTube Channel – https://www.youtube.com/channel/UCEj-fkwCUJGVW0-FmipRP3A

Hot this week

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Topics

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...

How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies

April 14, 2025  India’s pharmaceutical industry, a global powerhouse, sends...
spot_img

Related Articles

spot_imgspot_img